Graig Shockey

Dynport Vaccine Company, Llc

$9,887,057

Attributed

$9,887,057

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $4.3M · FY2018–24

$5M$3.8M$2.5M$1.3M$0

'18

'19

'20

'21

'22

'23

'24

Funding mix

By agency

NIH$9,887,057 · 1

By mechanism

N01$9,887,057 · 1

Top collaborators

No co-investigators on record.

Most similar at Dynport Vaccine Company, Llc

Same institution · by research overlap

Salama Balume$16,877,312
David Shumway$6,214,596
George Saviolakis$1,316,543
Casey Long$2,265,501
Abraham Kallarkal$10,500

Others in their field

Other Emerging Leaders on “Investigation”

Sonia M Thomas · Research Triangle Institute$700,865,642
Tracy L Nolen · Research Triangle Institute$474,487,152
Chanza Baytop · Westat, Inc.$271,217,917
Joel A Lipkin · Four Points Technology, Llc$178,737,225
Leonard Freedman · Leidos Biomedical Research, Inc.$132,914,619
Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$93,329,356

Research focus

InvestigationClinical Trials UnitPhase I Clinical TrialsInfectious Disease TreatmentNovel TherapeuticsTherapeutic AgentsNational Institute Of Allergy And Infectious DiseaseImmunomodulatorsCommunicable DiseasesClinical TrialsCarbapenem ResistanceAntibiotic ResistanceBacterial InfectionsBacterial Drug ResistanceInfectionEarly Phase Clinical TrialCombating Antibiotic Resistant BacteriaClinical Trial ImplementationGram-Negative BacteriaImmune Modulating AgentsNew AgentsPhase 0 Clinical TrialPreventionStudy Subject